TUESDAY, Nov. 27 A U.S. Food and Drug Administration advisory panel strongly recommended Tuesday that the Tamiflu well known as prescription flu drug (oseltamivir) must have a stronger warning on the label to reflect reports of bizarre behaviors and deaths among children who use the medication.
Related News:
- FDA Drug Safety Communication: Liver injury warning to be removed from Letairis (ambrisentan) tablets
- Concentration Lowered in Tamiflu Medication
- FDA Drug Safety Communication: Medication errors resulting from confusion between risperidone (Risperdal) and ropinirole (Requip)
- FDA announces new safety recommendations for high-dose simvastatin
- HHS RELEASE: FDA unveils final cigarette warning labels